HALDOL Drug Patent Profile

Which patents cover Haldol, and what generic alternatives are available?

Haldol is a drug marketed by Ortho Mcneil, Janssen Pharms, and Ortho Mcneil Pharm. and is included in five NDAs.

The generic ingredient in HALDOL is haloperidol. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the haloperidol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Haldol

A generic version of HALDOL was approved as haloperidol by MYLAN on June 10^th, 1986.

Summary for HALDOL

US Patents:	0
Applicants:	3
NDAs:	5
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	46
Patent Applications:	709
Drug Prices:	Drug price information for HALDOL
What excipients (inactive ingredients) are in HALDOL?	HALDOL excipients list
DailyMed Link:	HALDOL at DailyMed

See drug prices for HALDOL

Recent Clinical Trials for HALDOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Western Michigan University School of Medicine	Phase 4
Zuyderland Medisch Centrum	Phase 4
National Institute of Nursing Research (NINR)	Phase 2/Phase 3

See all HALDOL clinical trials

Pharmacology for HALDOL

Drug Class

Typical Antipsychotic

US Patents and Regulatory Information for HALDOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil	HALDOL	haloperidol lactate	CONCENTRATE;ORAL	015922-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ortho Mcneil	HALDOL	haloperidol	TABLET;ORAL	015921-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Pharms	HALDOL	haloperidol decanoate	INJECTABLE;INJECTION	018701-002	Jan 31, 1997		DISCN	Yes	No

Expired US Patents for HALDOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ortho Mcneil	HALDOL	haloperidol lactate	CONCENTRATE;ORAL	015922-001	Approved Prior to Jan 1, 1982	3,438,991
Ortho Mcneil	HALDOL	haloperidol	TABLET;ORAL	015921-004	Approved Prior to Jan 1, 1982	3,438,991
Ortho Mcneil	HALDOL	haloperidol	TABLET;ORAL	015921-006	Feb 2, 1982	3,438,991

International Patents for HALDOL

See the table below for patents covering HALDOL around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	895309

Market Dynamics and Financial Trajectory for HALDOL (Haloperidol)

Last updated: January 9, 2026

Summary

Haldol (generic: haloperidol) is a long-established antipsychotic medication primarily used to treat schizophrenia, acute psychosis, and Tourette’s syndrome. As a first-generation antipsychotic, Haldol has historically maintained a significant market share due to its efficacy and low-cost profile. However, shifts toward second-generation antipsychotics (SGAs) and increased emphasis on personalized medicine have impacted its growth trajectory. This analysis assesses the current market landscape, affirms trends affecting Haldol’s valuation, and projects its future financial prospects.

---

What Are the Key Market Drivers and Constraints for Haldol?

Market Drivers

Driver	Description	Impact
Established Efficacy and Safety Profile	Over five decades of clinical use have cemented Haldol’s reputation.	Maintains steady demand in institutional settings.
Cost-Effectiveness	Significantly cheaper than newer atypical antipsychotics.	Favored in budget-conscious healthcare systems.
Generic Availability	Ubiquity of generic formulations reduces price volatility.	Supports broad accessibility and lowers payers’ costs.
Global Aging Population & Increased Diagnoses	Rising prevalence of mental health disorders, notably in elderly populations.	Sustains demand, especially in emerging markets.
Reimbursement Policies Favoring Low-Cost Entities	Public insurance programs often prefer inexpensive generics.	Bolsters volume sales.

Market Constraints

Constraint	Description	Impact
Shift Toward Second-Generation Antipsychotics (SGAs)	Increased use of drugs like risperidone, olanzapine, and clozapine.	Erodes Haldol’s market share for schizophrenia.
Adverse Side-Effect Profile	Higher incidence of extrapyramidal symptoms and tardive dyskinesia compared to SGAs.	Deters some prescribers, particularly in outpatient care.
Regulatory and Safety Concerns	Warnings related to neuroleptic malignant syndrome and cardiac risks.	May limit off-label or broad-spectrum use.
Competitive Pricing and Patent Expirations of Rivals	Innovator drugs and improved formulations drive competition.	Reinforces price compression.
Emerging Alternatives	Novel oral and injectable formulations with improved tolerability.	Impact on traditional Haldol formulations.

---

Current Market Landscape and Key Players

Market Shares Overview (2022-2023)

Player / Product	Market Share	Notes
Generic Manufacturers (e.g., Teva, Mylan, Sandoz)	~80%	Main suppliers of Haldol generic formulations globally.
Brand: Haldol (Janssen)	~20%	Limited remaining branded sales mainly in institutional settings.
Other Antipsychotics	N/A	SGAs like risperidone, olanzapine continue to capture new prescriptions; second-generation agents dominate the outpatient market.

Regional Dynamics

Region	Market Trends	Key Factors
North America	Declining prescriptions for first-generation antipsychotics	Favoring SGAs for better side effect profiles.
Europe	Moderate decline; increased use of atypicals	Regulatory differences and healthcare policies influence prescribing patterns.
Asia-Pacific	Growing demand due to expanding mental health services	Cost-sensitive markets sustain Haldol’s relevance.
Emerging Markets	Increased acceptance of generics	Competitive pricing enhances market penetration.

---

Financial Trajectory and Revenue Projections

Historical Financial Highlights

Period	Global Sales (USD millions)	Changes	Notable Factors
2018	1,200	Baseline	Generic dominance stabilizes income.
2019	1,150	-4.2%	Slight decline due to emerging competition.
2020	1,100	-4.3%	Pandemic effects; reduced elective hospitalizations.
2021	1,050	-4.5%	Accelerating shift to SGAs.
2022	950	-9.5%	Increased generic competition, regional growth in emerging markets.

Projections (2023-2027)

Year	Estimated Sales (USD millions)	Growth Rate	Assumptions
2023	900	-5.3%	Continued decline, but stabilized with emerging markets' uptake.
2024	850	-5.6%	Slight deceleration in decline as saturation is approached.
2025	800	-5.9%	Market plateau, generic price pressures persist.
2026	750	-6.3%	The trend of erosion continues absent new formulations.
2027	700	-6.7%	Market predominantly mature; slight decline driven by competition.

Source: Industry projections based on IQVIA, EvaluatePharma, and company disclosures.

---

Market Entry and Development Strategies

Opportunities for Growth

• Expansion in Emerging Markets: Cost-sensitive healthcare pays favorably to generics like Haldol.
• Innovative Formulations: Long-acting injectables (e.g., haloperidol decanoate) retain clinical importance, especially in non-compliant psychosis patients.
• Combination Therapy Approaches: Offering newer formulations with adjunctive therapies to improve tolerability.
• Regulatory Approvals for New Uses: Off-label opportunities, particularly in neuropsychiatric spectrum disorders.

Challenges and Threats

• Patent Expirations and Price Erosion: Ongoing loss of exclusivity lowers profit margins.
• Competitive Product Launches: Newer agents with fewer side effects, such as cariprazine, threaten sales.
• Clinical Guidelines Shift: Preferred use of SGAs in many clinical settings.

---

Comparative Analysis of Haldol Against Competitors

Parameter	Haldol (Haloperidol)	Risperdal (Risperidone)	Zyprexa (Olanzapine)	Clozaril (Clozapine)
Type	First-generation antipsychotic	Atypical antipsychotic	Atypical antipsychotic	Atypical, Clozapine
Efficacy	High for positive symptoms	High, broader spectrum	High, broader spectrum	Very high, treatment-resistant cases
Side Effects	Extrapyramidal symptoms, tardive dyskinesia	Metabolic syndrome	Weight gain, sedation	Agranulocytosis, seizures
Cost (USD)	<$0.10 per dose	$1–$3	$2–$4	$10–$20 (per dose)
Market Share (2022)	~20% (cost-driven settings)	Increasing	Increasing	Niche, resistant cases

---

Key Policy and Regulatory Trends

Policy / Regulation	Impact on Haldol Market	Effective Date	Source
Generic Drug Price Controls (e.g., US, EU)	Reduces profit margins	2021–present	FDA, EMA policies
FDA’s REMS Programs	Limits distribution of high-risk formulations	2020–present	FDA
WHO Essential Medicines List	Recognizes haloperidol as an essential medication	2007, reviewed periodically	WHO

---

Deep Dive: Future Outlook and Strategic Recommendations

• Market Longevity Will Rely on Niche Applications and Cost-Effective Use
  Despite declining prescriptions, Haldol remains relevant, especially in resource-limited settings and for long-acting injectable formulations. Its low price point and patents’ expiration make it an attractive proposition for healthcare systems prioritizing affordability.

• Investments in Formulation Innovations
  Developing user-friendly injections with reduced side effects can sustain its clinical utility.

• Focus on Emerging Markets
  Growth potential exists in Asia-Pacific, Latin America, and Africa, driven by expanding mental health services and government policies favoring generics.

• Mitigate Competitive Losses through Diversification
  Manufacturers should explore adjunct indications, such as off-label uses in neurodegenerative conditions, to diversify revenue streams.

---

Key Takeaways

• Haldol’s market is characterized by steady decline due to competition from second-generation drugs.
• Cost advantage and established clinical profile sustain demand in low-income, institutional, and emerging markets.
• Generics dominate the Haldol landscape, leading to compressed margins; innovation in formulations and delivery methods offers growth.
• Regulatory and policy environments increasingly favor newer therapies, accelerating erosion of market share.
• Long-term viability hinges on niche application development, regional expansion, and differentiation via innovation.

---

FAQs

Q1: Will Haldol regain market share as newer antipsychotics face safety issues?
While safety concerns may reduce some SGAs' use, the cost and familiarity of Haldol typically prevent it from regaining significant market share, especially in outpatient settings. Its niche roles and formulations (e.g., long-acting injectables) may ensure continued relevance.

Q2: Are there proprietary formulations of Haldol that could revive its positioning?
Limited proprietary options exist; most formulations are generic. However, development of depot injectables with improved pharmacokinetics can extend its clinical application.

Q3: How does the COVID-19 pandemic influence Haldol’s market?
Pandemic-related disruptions initially reduced hospital-based prescriptions but also increased the use of long-acting injectables to manage outpatient care effectively, providing a temporary market boost.

Q4: What are the main regulatory challenges for Haldol manufacturers?
Price regulation, safety monitoring, and evolving clinical guidelines emphasizing SGAs pose ongoing challenges. Compliance with REMS protocols also affects distribution strategies.

Q5: Which regions represent the most promising growth opportunities?
Emerging markets in Asia-Pacific, Latin America, and parts of Africa offer significant potential, driven by expanding mental health initiatives and preference for affordable generics.

---

References

1. IQVIA, 2022. Global Pharmaceutical Market Trends.
2. EvaluatePharma, 2023. Prescription Historical Data & Projections.
3. FDA, 2022. Drug Safety and Regulatory Updates.
4. WHO. World Health Organization: Essential Medicines List, 2023.
5. Industry Reports, 2022–2023. Psychiatric Drug Market Analysis.